Physician profile
Charles V Roche
NPI 1477680304
$5,800.30
in general payments reported to CMS, 2019-2025
29 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $2,550 · 2021: $931 · 2022: $1,175 · 2023: $119 · 2024: $92.52 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $2,067.79 | 2020-2022 | |
| Novo Nordisk INC | $1,162.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $466.54 | 2019-2023 | Vraylar, Ubrelvy, Dalvance |
| Philips North America LLC | $299.05 | 2020-2022 | |
| Lilly USA, LLC | $257.24 | 2019-2025 | Mounjaro |
| Astellas Pharma US INC | $192.46 | 2019-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $152.31 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $142.06 | 2019-2025 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $126.20 | 2019-2024 | Zoryve |
| Amgen INC. | $112.37 | 2019-2023 | Repatha, Otezla |
| Currax Pharmaceuticals LLC | $100.26 | 2021-2022 | |
| Amarin Pharma, INC. | $96.42 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.18 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $69.41 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $65.17 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $61.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.31 | 2020-2022 | |
| Abbott Laboratories | $42.18 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.22 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $29.79 | 2020-2022 | |
| Daiichi Sankyo INC. | $28.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $26.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.73 | 2024 | Voquezna |
| Medtronic, INC. | $13.45 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2021 | |
| Medtronic Vascular, INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Roche listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.